Two organizations representing patients have demanded a common system of price-fixing for new drugs in Europe.
Tired of the continuous debate over the increasingly high cost of medications, 2 organizations representing patients have demanded a common system of price-fixing for new drugs in Europe. The 2 organizations, the European Patients Forum and the European Organisation for Rare Diseases, have called for a common payment formula for all European nations, rather than have each nation develop it's own nationalized payment and reimbursement scheme. The thought behind the demand is that the united front presented by multiple nations would have a better bargaining power, which would reduce the drug developer's profits.
The groups want a radical new system to ensure patients have access to new medicines without compromising on the sustainability of healthcare systems.
Complete article on Politico: http://politi.co/1IW7H2F
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More